Skip to main content

Advertisement

Table 1 Pathology of invasive BRCA2 female and male breast tumours and ORs in predicting male BRCA2 mutation carrier status

From: Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

  Females Males Unadjusted OR (95 % CI) Adjusted ORa (95 % CI)
  Number Percent Number Percent   
Totalb 3750   326    
Morphology
 Ductal carcinoma 2693 83.6 253 95.1 Reference Reference
 Lobular carcinoma 276 8.6 4 1.5 0.15 (0.06–0.41) 0.14 (0.05–0.43)
 Medullary carcinoma 60 1.9 2 0.8 0.35 (0.09–1.46) 0.46 (0.10–2.11)
 Other 193 6.0 7 2.6 0.39 (0.18–0.83) 0.54 (0.24–1.23)
TNM stage
 0–1 560 40.2 44 29.5 Reference Reference
 2 629 45.1 70 47.0 1.42 (0.95–2.10) 1.97 (1.20–3.23)
 3–4 205 14.7 35 23.5 2.17 (1.37–3.44) 3.55 (1.96–6.44)
Histologic grade
 Grade 1 149 5.9 8 3.5 Reference Reference
 Grade 2 1057 41.7 92 39.8 1.62 (0.77–3.41) 1.88 (0.76–4.67)
 Grade 3 1329 52.4 131 56.7 1.84 (0.88–3.83 2.66 (1.08–6.55)
Lymph node status
 Negative 1398 52.4 123 50.2 Reference Reference
 Positive 1270 47.6 122 49.8 1.09 (0.84–1.43) 1.55 (1.12–2.14)
ER status
 Negative 650 22.7 8 3.3 Reference Reference
 Positive 2211 77.3 236 96.7 8.67 (4.26–17.66) 10.59 (5.15–21.80)
PR status
 Negative 892 35.0 30 13.2 Reference Reference
 Positive 1654 65.0 198 86.8 3.56 (2.41–5.26) 5.04 (3.17–8.04)
HER2 status
 Negative 1404 85.9 126 83.4 Reference Reference
 Positive 230 14.1 25 16.6 1.21 (0.77–1.90) 1.22 (0.70–2.11)
Subtypes
 ER+ and/or PR+, HER2− 1112 69.8 118 81.9 Reference Reference
 ER+ and/or PR+, HER2+ 182 11.4 22 15.3 1.14 (0.70–1.84) 1.18 (0.65–2.13)
 ER−, PR−, HER2+ 40 2.5 2 1.4 0.47 (0.11–1.98) 0.42 (0.09–1.98)
 Triple-negative (ER−, PR−, HER2−) 260 16.3 2 1.4 0.07 (0.02–0.30) 0.05 (0.01–0.22)
 ER+ and/or PR+, HER2− vs. others      0.51 (0.33–0.79) 0.42 (0.25–0.70)
  1. BRCA2 breast cancer 2, early onset gene, CI confidence interval, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, OR odds ratio, PR progesterone receptor, TNM tumour, node, metastasis
  2. Significant results are indicated by boldface type
  3. aAnalyses adjusted for country, age at diagnosis and calendar year of diagnosis
  4. bSome data for each pathologic feature are not available